The stock of Cara Therapeutics Inc (NASDAQ:CARA) is a huge mover today! The stock decreased 6.47% or $1.05 on December 11, hitting $15.17. About 296,536 shares traded hands. Cara Therapeutics Inc (NASDAQ:CARA) has risen 51.40% since May 11, 2015 and is uptrending. It has outperformed by 55.81% the S&P500.
The move comes after 9 months negative chart setup for the $441.70 million company. It was reported on Dec, 12 by Barchart.com. We have $13.50 PT which if reached, will make NASDAQ:CARA worth $48.59 million less.
Out of 7 analysts covering Cara Therapeutics (NASDAQ:CARA), 7 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cara Therapeutics was the topic in 3 analyst reports since July 27, 2015 according to StockzIntelligence Inc.
According to Zacks Investment Research, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.” Get a free copy of the Zacks research report on Cara Therapeutics Inc (CARA).
The institutional sentiment decreased to 2.64 in Q3 2015. Its down 0.10, from 2.74 in 2015Q2. The ratio worsened, as 7 funds sold all Cara Therapeutics Inc shares owned while 18 reduced positions. 25 funds bought stakes while 41 increased positions. They now own 23.11 million shares or 91.92% more from 12.04 million shares in 2015Q2.
Rho Capital Partners Inc holds 12.66% of its portfolio in Cara Therapeutics Inc for 2.67 million shares. Opaleye Management Inc. owns 415,000 shares or 2.92% of their US portfolio. Moreover, Dafna Capital Management Llc has 1.33% invested in the company for 93,574 shares. The Ohio-based Mpam Credit Trading Partners L.P. has invested 0.9% in the stock. Wall Street Associates, a California-based fund reported 311,000 shares.
Since May 5, 2015, the stock had 0 insider buys, and 3 insider sales for $299,665 net activity. Menzaghi Frederique Ph.D. sold 6,000 shares worth $83,715. Lewis Michael E sold 7,262 shares worth $68,989. Slagel Dean sold 188,811 shares worth $1.89 million.
Cara Therapeutics Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.